(Q37362658)

19 August 2017

1 reference

title

Omalizumab in the treatment of severe asthma: efficacy and current problems (English)

1 reference

19 August 2017

0 references

1

Girolamo Pelaia

1 reference

19 August 2017

4

Maria Teresa Busceti

1 reference

19 August 2017

Teresa Renda

2

1 reference

19 August 2017

Pasquale Romeo

series ordinal

3

1 reference

19 August 2017

Rosario Maselli

series ordinal

5

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Therapeutic advances in respiratory disease

19 August 2017

published in

1 reference

19 August 2017

volume

2

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

409-421

1 reference

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Churg-Strauss vasculitis in a patient treated with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Immunology of asthma and chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The pharmacological basis of anti-IgE therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

IgE in allergy and asthma today

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Targeting airway inflammation in asthma: current and future therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Epidemiology of asthma: the year in review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Anti-immunoglobulin E therapy with omalizumab for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Treatment strategies for allergy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

An overview of EPR3 asthma guidelines: what's different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Omalizumab is effective in the long-term control of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The role of T lymphocytes in the pathogenesis of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The global burden of asthma: executive summary of the GINA Dissemination Committee report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Severe asthma and the omalizumab option.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Airway remodeling contributes to the progressive loss of lung function in asthma: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

New perspectives in asthma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The use of omalizumab in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Asthma treatment: 'magic bullets which seek their own targets'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

A new perspective on concepts of asthma severity and control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

Severe asthma: lessons from the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

21 January 2018

Omalizumab for asthma.

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465808100431

21 January 2018

Identifiers

DOI

10.1177/1753465808100431

1 reference

19 August 2017

1 reference